Gmax's GMA106, second generation obesity/T2DM/NASH mAb gives first in human dose

HANGZHOU,China,Nov. 11,2021 -- Gmax Biopharm today announces that the first dose of GMA106 was given to human subjects in a phase 1 study to investigate the safety,pharmacokinetics,and pharmacodynamics of this drug in the treatment of obesity. The study is a single dose,placeable controlled,double blind,randomized,dose escalating study,with 6 dose cohorts each containing 8 subjects. The dosages are 4,10,20,40,60,and 80mg. Gmax is also in the process of filing INDs for phase 1b/2 trials in China and USA.

"We are extremely excited about this event as GMA106 shows superior efficacy in weight reduction of non-human primate in pre-clinical studies. It can be a significant breakthrough as the second generation of drugs in our developmental pipeline for the treatment of obesity and T2DM. While GMA102 (T2DM) is already in phase 3 trial in China,GMA106 offers hope to fill more unmet medical needs in the obesity/T2DM areas. Additionally,this new drug could be used in combination with GMA102 for even better treatment of T2DM and obesity",said Dr. Shuqian Jing,founder and CEO of Gmax.

About GMA106: GMA106 is Gmax's second generation mAb therapy for the treatment of obesity/T2DM/NASH. It is rationally designed utilizing Gmax's GPCR mAb and M-Body technologies. This M-Body is composed of an anti-GIPR antibody fused with a GLP-1 peptide. It can simultaneously interact with GLP-1R and GIPR and regulate both signaling pathways to synergistically suppress appetite,reduce blood glucose and fat accumulation,and improve insulin resistance. Therefor GMA106 is a new and potentially a better treatment for obesity,diabetes and NASH (non-alcohol steatohepatitis).

About Gmax Biopharm LLC.: Gmax is a clinical stage biopharmaceutical company established in 2010 and headquartered in Hangzhou,China. It's a global company focusing on R&D,production and commercialization of antibody drugs targeting GPCRs. Gmax mainly works on cardiovascular,metabolic and cancer areas. Currently there are five drug development programs in different stages of clinical trials: GMA102 (type 2 diabetes),GMA105 (obesity),GMA301A (PAH for adult),GMA301B (PAH for children),GMA106 (obesity/T2DM/NASH). GMA131,an ETA specific ERA mAb for DKD/CKD,is about to enter into phase 1/2 trial in China and USA. Gmax's unique M-body technology empowers acting on two or more different targets to improve drug efficacy or broaden indications.

www.gmaxbiopharm.com

Contact: IR@gmaxbiopharm.com

View original content:https://www.prnewswire.com/news-releases/gmaxs-gma106-second-generation-obesityt2dmnash-mab-gives-first-in-human-dose-301421963.html